Many hoped the end of 2023 would bring some solace for biotech after nearly two years of challenging market conditions. As the year nears its end, that relief remains largely out of reach, as cuts to both teams and pipelines continue to climb. Today, at least three more biotechs have tossed candidates into the ever-growing pile of discontinued programs.
First up is Adaptimmune Therapeutics, a biotech terminating two programs dubbed Gavo-cel and TC-510. After a review of safety and efficacy data for both candidates, the T-cell therapy company didn’t “see a path forward” for further development of either programs, according to a third-quarter earnings release.
The blow comes after GSK paid Adaptimmune 30 million pounds ($37.3 million) to wipe its hands of two programs this spring. One of the programs was lete-cel, an asset Adaptimmune had at one point touted as its leading cell therapy.
As the biotech awaits an FDA approval decision for its investigational therapy targeting MAGE-A4 in solid tumors, dubbed Afami-cel, discovery work will continue with Roche’s Genentech on two allogeneic programs.
The second biotech cutting programs is Monte Rosa Therapeutics, a Boston-based biotech with a molecular glue platform. In a move to prioritize resources, the company is discontinuing an early-stage sickle cell program. Not much is known beyond that, as little was publicly revealed about the discovery program. The company will focus on other programs, such as its clinical-stage GSPT1-directed candidate called MRT-2359 and work with Roche, who inked a deal last month for the use of Monte Rosa’s QuEEN platform to target cancer and neurological diseases previously considered out of reach.
Instead, Intellia intends to advance a different AATD research-stage program that uses the company’s DNA writing technology. Intellia, which reported earnings this morning, saw its stock tumble 12% from $28.45 at market open this morning to $25.03 at 11 a.m. ET.
Less than a month ago, Intellia received the FDA green light to study NTLA-2001, an in vivo CRISPR-based gene editing therapy in the U.S. The company worked with sites in Europe and New Zealand to study the therapy in a phase 1 trial and showed NTLA-2001 may safely reduce levels of misfolded TTR, a protein that drives the rare, life-threatening disease ATTR amyloidosis. The new FDA allowance positions the company to start a phase 3 trial of the Regeneron-partnered candidate by the end of the year.
Editor's note: This article was updated at 9:30 a.m. ET Nov. 10 with revisions to information provided about lete-cel.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.